Feasibility of using recombinant factor VIIa in continuous infusion

Thrombosis and Haemostasis

Volumn 75, Issue 3, 1996, Pages 432-436

  Schulman, S ^a,d   Jensen, M Bech ^b   Varon, D ^a   Keller, N ^c   Gitel, S ^a   Horoszowski, H ^d   Heim, M ^a   Martinowitz, U ^a  

^a The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

^b NOVO NORDISK A S   (Denmark)

^c Department of Clinical Microbiology ^*  (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LIDOCAINE; LOW MOLECULAR WEIGHT HEPARIN; PHTHALIC ACID DIBUTYL ESTER; PHTHALIC ACID DIOCTYL ESTER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SODIUM CHLORIDE; TRANEXAMIC ACID;

ADULT; ARTICLE; BACTERIAL GROWTH; CASE REPORT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG OXIDATION; DRUG STABILITY; ENVIRONMENTAL TEMPERATURE; ESCHERICHIA COLI; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; KNEE ARTHROPLASTY; MALE; MINIPUMP; PRIORITY JOURNAL; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; THROMBOPHLEBITIS; WOUND HEALING;

EID: 9044249714     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650292     Document Type: Article

References (13)

1. Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol 1994; 1: 471-8.
2. Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34.
3. Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: Stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72: 403-7.
4. Schulman S, Kelter N, Gitel N, Ravid B, Varon D, Martinowitz U. The suitability of recombinant F VlII (Kogenate®) for continuous infusion - stability and bacteriological safety. Br J Haematol 1994; 87 (Suppl 1): 185 (abstract).
5. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIlI products in the treatment of von Willebrand disease. Thromb Haemost 1994; 71: 173-9.
6. Schulman S, Gitel S, Zivelin A, Mandalaki T, Katsarou O, Varon D, Martinowitz U. The feasibility of using concentrates containing factor IX for continuous infusion Haemophilia 1995; 1: 103-10.
7. Gordon EM, Al-Batniji F, Goldsmith JC. Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII. Am J Hematol 1994; 45: 142-5.
8. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
9. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
10. Broze G, Majerus PT. Human factor VII. Methods Enzymol 1981; 10: 228-37.
11. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis 1991; 21: 1-4.
12. Hedner U. Experiences with recombinant factor VIIa in haemophiliacs. In: Biotechnology of plasma proteins. Albertini A, Lenfant CL, Mannucci PM, Sixma JJ, eds. Curr Stud Hematol Blood Transf. Karger, Basel 1991; 58: pp 63-8.
13. Ingerslev J, Sneppen O, Knudsen L, Sindet-Pedersen S. Effect of recombinant factor VIIa (rFVIIa) in surgical procedures in haemophilia A patients with inhibitors and congenital factor VII deficiency. In: 24. Hämophilie-Symposium, Hamburg 1994. Scharrer/Schramm, eds. Springer, Berlin - Heidelberg 1994: pp 122-5.